Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy

BACKGROUND: Bringing antibodies from pre-clinical studies to human trials requires humanization, but this process may alter properties that are crucial for efficacy. Since pathological tau protein is primarily intraneuronal in Alzheimer's disease, the most efficacious antibodies should work bot...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EBioMedicine
Autors principals: Congdon, Erin E., Chukwu, Jessica E., Shamir, Dov B., Deng, Jingjing, Ujla, Devyani, Sait, Hameetha B.R., Neubert, Thomas A., Kong, Xiang-Peng, Sigurdsson, Einar M.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
Research paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6492224/
https://ncbi.nlm.nih.gov/pubmed/30910484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.03.033
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars